Some MacroGenics, Inc. (MGNX) Institutional Investors Are Quietly Pulling Out

MacroGenics, Inc. (NASDAQ:MGNX) produced a 28.14% rally since recording the worst price of $11.16. Thanks to the latest 3.17% increase, it now trades at $14.3. Throughout the trading on 01/11/2019, the share price floated between $13.59 and $14.6. This company shares are 121.89% off its target price of $31.73 and the current market capitalization stands at $585.73M. The recent change has given its price a -6.54% deficit over SMA 50 and -56.32% deficit over its 52-week high. The stock witnessed 0.7% gains, -24.89% declines and -35.67% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MGNX’s volatility during a week at 5.77% and during a month it has been found around 5.73%.

MacroGenics, Inc. (MGNX) Top Holders

Institutional investors currently hold around $529 million or 88.2% in MGNX stock. Look at its top three institutional owners. Oppenheimerfunds, Inc. owns $58.46 million in MacroGenics, Inc., which represents roughly 9.98% of the company’s market cap and approximately 11.05% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 3,225,256 shares of the stock are valued at $46.12 million. The third largest holder is Bb Biotech Ag, which currently holds $42.76 million worth of this stock and that ownership represents nearly 7.3% of its market capitalization.

MacroGenics, Inc. 13F Filings

At the end of September reporting period, 58 institutional holders increased their position in MacroGenics, Inc. (NASDAQ:MGNX) by some 2,695,439 shares, 56 decreased positions by 4,101,186 and 29 held positions by 30,223,822. That puts total institutional holdings at 37,020,447 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 409,404 shares while 12 institutional investors sold out their entire positions totaling 1,715,490 shares.

MacroGenics, Inc. (NASDAQ:MGNX) Insider Trades

Multiple company employees have indulged in significant insider trading. MacroGenics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Sr VP & Chief Business Officer Risser Eric Blasius has sold 1,000 shares of MacroGenics, Inc. (MGNX) in trading session dated Mar. 12, 2018. These shares are worth $31,080 and were traded at $31.08 each. The SEC filing shows that Karrels James performed a sale of 5,000 shares. The SVP, CFO and Secretary disposed these shares by way of transaction on Mar. 05, 2018. The company’s shares were given away at $31 per share worth to an income of some $155,000 on account of Karrels James.

Sr VP & Chief Business Officer, Risser Eric Blasius, sold 4,000 common shares of MacroGenics, Inc. (MGNX) in the open market. In a transaction dated Mar. 02, 2018, the shares were put up for sale at an average price of $30, raking in a sum of $120,000. After this sale, 9,100 common shares of MGNX are directly owned by the insider, with total stake valued at $130,130.

In the transaction dated Feb. 28, 2018, the great number of shares disposed came courtesy the VP, Controller and Treasurer; Cilinski Lynn disposed a total of 23,967 shares at an average price of $25.01, amounting to approximately $599,415. The insider now directly owns 1,923 shares worth $27,499.

MacroGenics, Inc. (MGNX) Analyst Guide

Several analysts have released their opinion on MacroGenics, Inc. (NASDAQ:MGNX), with 4 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.82 average brokerage recommendation.